Public perceptions of lung cancer screening: a population-based assessment of acceptability and feasibility [0.03%]
基于人群的肺部癌症筛查公众认知评估：可接受性和可行性
Claire Chenwen Zhong,Zehuan Yang,Mingtao Chen et al.
Claire Chenwen Zhong et al.
Background: Despite strong evidence supporting screening in reducing lung cancer mortality, uptake remains low globally. This study aimed to assess the public perceptions of the acceptability and feasibility of lung cance...
Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trial [0.03%]
一项AIO一期b/二期试验：在经治的晚期或转移性肺腺癌患者中，nintedanib联合nivolumab治疗的可行性和安全性
Martin Reck,Cornelius Waller,Parvis Sadjadian et al.
Martin Reck et al.
Objectives: Nivolumab and nintedanib are both established agents for pre-treated NSCLC of adenocarcinoma histology. Hypothesizing that the combination of immune checkpoint inhibition (nivolumab) and anti-angiogenesis (nin...
Altered bacteriome and mycobiome in small cell lung cancer: insights from microbial profiling [0.03%]
小细胞肺癌中菌群和真菌群的改变——来自微生物谱分析的见解
Ines Rolim,Antonio Lopez-Beltran,Marcos Pantarotto et al.
Ines Rolim et al.
Background: The tumor-associated microbiome influences cancer development and progression, yet the microbial landscape of small cell lung cancer (SCLC) remains unexplored. Given the absence of SCLC-specific microbiome stu...
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis [0.03%]
Amivantamab联合Lazertinib与Osimertinib一线治疗亚洲EGFR突变晚期NSCLC患者的总生存期：MARIPOSA子集分析
Hidetoshi Hayashi,Byoung Chul Cho,Yu Jung Kim et al.
Hidetoshi Hayashi et al.
Background: Approximately 60 % of lung cancer cases occur in Asia, indicating an epidemiological disparity and need for effective therapies. Amivantamab-lazertinib is approved for first-line EGFR-mutated advanced non-smal...
Broadening clinical trial inclusivity of patients with lung cancer and brain metastases utilizing the Graded Prognostic Assessment (GPA): A call to action [0.03%]
利用分级预后评估(GPA)扩大脑转移肺癌患者临床试验纳入范围——行动呼吁
Laura Alder,Trey C Mullikin,Chris Lascola et al.
Laura Alder et al.
Brain metastases (BM) occur in 30-50% of non-small cell lung cancer (NSCLC) and up to 80% of small cell lung cancer (SCLC) patients, yet historically over 80% of clinical trials excluded this population. Current eligibility requirements oft...
Response to Letter to the Editor entitled "Methodological considerations in assessing the clinical impact of TP53 classifications in advanced NSCLC" [0.03%]
关于题为“评估TP53分类在晚期NSCLC中临床影响的方法学考虑”的编辑来信的回复
Deborah Di-Xin Zhou,Chee Khoon Lee
Deborah Di-Xin Zhou
Safety evaluation of tarlatamab: A pharmacovigilance study based on the FAERS database [0.03%]
基于FAERS数据库的Tarlatamab的安全性评价：一项药物警戒研究
Jiesong Wang,Xue Wang,Yaxin Li et al.
Jiesong Wang et al.
Objectives: Tarlatamab (Imdelltra, AMG757) has been approved for extensive-stage small cell lung cancer (ES-SCLC) treatment, yet post-marketing data remain limited. Existing studies lack conclusive evidence on its real-wo...
Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patients [0.03%]
意大利肺癌患者中基于患者的不良事件通用术语标准（PRO-CTCAE）有效性和灵敏度的验证研究
Maria Lucia Iacovino,Laura Arenare,Alessandro Morabito et al.
Maria Lucia Iacovino et al.
Background: Patient-reported symptom monitoring may improve the outcomes of cancer treatment. Knowledge of psychometric properties may drive the selection of optimal tools. Here we report the analysis of PRO-CTCAE in Ital...
HDAC1-modified lamin A/C drives nuclear deformation in RB1-deficient lung adenocarcinoma [0.03%]
RB1缺陷型肺腺癌中乙酰化组蛋白去乙酰酶1修饰的核纤层A/C驱动细胞核变形
Hongxia Li,Yu Chen,Lihong Wei et al.
Hongxia Li et al.
Background: Lineage transformation from lung adenocarcinoma (LUAD) to small cell lung cancer (SCLC) represents a rare yet well-documented off-target mechanism associated with acquired resistance to tyrosine kinase inhibit...
Deep exploration of sotorasib-related hepatobiliary AEs: Based on FDA Adverse Event reporting system [0.03%]
基于美国食品药品监督管理局不良事件上报系统的sotorasib相关肝胆系统不良反应的深度挖掘分析
Xinmei Pan,Lin Zhang,Linli Xie et al.
Xinmei Pan et al.
Objectives: This study focused on the exploration of sotorasib-related hepatobiliary adverse events (AEs) through the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, to provide reference f...